The FDA recently approved the dual CDK4/6 inhibitors Palbociclib, robocalled, and abaculi in combination with other medications for the treatment of hormone receptor positive (HR+) advanced or metastatic breast cancer as well as other breast cancer subtypes (Ding et al., 2020). Here, NR4A1 is linked to breast carcinoma.